Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Large B-Cell, Diffuse 13Recurrence 9Leukemia, Myeloid, Acute 9Leukemia 8Hodgkin Disease 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma 5Myelodysplastic Syndromes 4Lymphoma, Non-Hodgkin 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Lymphocytic, Chronic, B-Cell 4Congenital Abnormalities 4Burkitt Lymphoma 4Myeloproliferative Disorders 3Lymphoma, Mantle-Cell 3Blast Crisis 3Thrombocythemia, Essential 2Primary Myelofibrosis 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Accelerated Phase 2Waldenstrom Macroglobulinemia 1Precancerous Conditions 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1

Interventions

Decitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extranodal Extension × Decitabine × Lymphoid × Clear all
NCT05816746 2023-05-09

Decitabine and Anti-PD-1 in R/R DLBCL

Chinese PLA General Hospital

Phase 2 Unknown
20 enrolled
Lymphoid

Extranodal Extension, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡